AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
04 3월 2025 - 4:35PM
PRESS RELEASE
ARTICLE FROM THE LEADING PUBLICATION
LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE’S MASITINIB AND ITS
PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK
VERMERSCH
Paris, March 04, 2025, 8.30am CET
-
Professor Patrick Vermersch is a distinguished neurologist
considered as one of the most influential key opinion leaders in
his field
-
According to Professor Patrick Vermersch, mast and
microglia cells’ pro-inflammatory activity could play a catalyst
role in the neurodegenerative process of several indications as
multiple sclerosis (MS), amyotrophic lateral sclerosis, Alzheimer’s
diseases and Parkinson’s disease
-
Expected phase III data of Masitinib, could position AB
Science’s leading compound as a breakthrough treatment in
Progressive MS Treatment due to its unique mechanism of action
which targets these two cells of the innate immune system, mast
cells and microglia
AB Science SA (Euronext -
FR0010557264 - AB) today announces that The Life Sciences Magazine,
a leading publication in the fields of healthcare and medical
advancements, has featured an exclusive cover story on Professor
Patrick Vermersch, principal investigator of phase 3 confirmatory
study with masitinib in progressive forms of multiple sclerosis. A
distinguished neurologist and Director of the Graduate School for
Biology and Health at the Université de Lille, Patrick Vermersch is
recognized among The Most Influential Leaders in Neurology 2025,
pioneering contributions to multiple sclerosis (MS) research and
reshaping the landscape of neurology, with masitinib emerging,
among other therapeutic options, as a potential game-changer in
progressive MS treatment.
-
Central role of neuroinflammation
According to Professor Patrick Vermersch,
neuroinflammation plays a significant role in neurodegenerative
disorders such as multiple sclerosis, amyotrophic lateral
sclerosis, Alzheimer’s diseases, and Parkinson’s disease.
Incidentally, masitinib targets two cells of the innate immune
system, mast cells and microglia, that are key in the modulation of
this neuroinflammation process. These cells’ pro-inflammatory
activity can act as a catalyst in the neurodegenerative process,
suggesting that addressing their harmful roles could be crucial in
managing these conditions.
-
Masitinib: a breakthrough in progressive MS treatment
Vermersch’s research has centered on emerging
potential of masitinib in treating progressive multiple sclerosis,
a debilitating condition with limited therapeutic options. In
collaboration with AB Science, his team has been evaluating
masitinib’s efficacy in targeting microglial cells and mast cells,
which play a crucial role in neuroinflammation and disease
progression.
Key highlights from the research include:
-
Masitinib’s positive effects on innate immunity, offering a novel
approach to treating progressive multiple sclerosis.
-
Phase IIB/III trials showing promising results in reducing
neuroinflammation and slowing disease progression.
-
Potential long-term benefits, with phase III data expected to
further clarify which patient groups could benefit most.
The article is available through the following
link:
https://thelifesciencesmagazine.com/patrick-vermersch-neurology/
About The Life Sciences
MagazineThe Lifesciences Magazine is a global healthcare
solutions platform that paves the way for various healthcare
innovations, expert advice, and acumen, and the success stories of
professionals in the field who are driving transformation with
their innovative thinking.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, inflammatory diseases and viral
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s
website: www.ab-science.com.
Forward-looking Statements - AB
ScienceThis press release contains forward-looking
statements. These statements are not historical facts. These
statements include projections and estimates as well as the
assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial
results, events, operations, future services, product development
and their potential or future performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
Ab Science (EU:AB)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Ab Science (EU:AB)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
